COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 3 FDA records to the applicant name Medtronic. The collection includes 1 510(k) clearance. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Nov 20, 2012 to Oct 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code DSQ appears in 2 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P100047, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 8200 Coral Sea St. NE, Mounds View, MN, 55112, US. Recorded on K261792, decision dated Oct 23, 2026.
Device categories in this collection
Ventricular (Assist) Bypass.
Changes described in PMA records
The FDA recorded an approval decision on 2026-09-23 for P100047/S241, a Special (Immediate Track) supplement to the HeartWare® HVAD System premarket approval held by Medtronic. The device falls under the ventricular (assist) bypass category, cardiovascular specialty, product code DSQ. The supplement reason is listed as a labeling change covering indications, instructions, shelf life or tradename.
The recorded scope is limited to labeling: updates reflecting previously approved design changes, strengthened existing cybersecurity warnings, and editorial changes. This action does not constitute a new approval of the HVAD System as a whole, and the source record does not specify which labeling sections changed, the wording of the cybersecurity warnings, or the design changes referenced. No supporting documents were included, so those details remain unknown from this record.
FDA approval-order wording
Approval for labeling updates to reflect previously approved design changes, strengthen existing cybersecurity warnings, and make editorial changes.
Sep 23, 2026 · Special (Immediate Track)FDA’s recorded scope: APPROVAL FOR THE HEARTWARE VENTRICULAR ASSIST SYSTEM (VAS). THIS DEVICE IS INDICATED FOR USE AS A BRIDGE TO CARDIAC TRANSPLANTATION IN PATIENTS WHO ARE AT RISK OF DEATH FROM REFRACTORY END-STAGE LEFT VENTRICULAR HEART FAILURE. THE HEART WARE VAS IS DESIGNED FOR IN-HOSPITAL AND OUT-OF-HOSPITAL SETTINGS, INCLUDING TRANSPORTATION VIA FIXED WING AIRCRAFT OR HELICOPTER.
Nov 20, 2012Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.